ClinicalTrials.gg
CompletedNCT00415168Updated Aug 17, 2010Results posted

Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer

A Phase 2 interventional study of pemetrexed and cisplatin in Gastric Cancer, sponsored by Eli Lilly and Company. Completed at 6 sites in Russian Federation. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-08-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing cisplatin in Stomach Neoplasms — 7 open to participants now, 8 under way, 2 of them phase 3. Cisplatin · Stomach Neoplasms.

Enrollment
35th of 90
53 · median 48
Started
2006
with 6 others
Phase 2
63 of 98
4 open now
Registered
41st of 98
by date

Among the 98 studies testing cisplatin in Stomach Neoplasms, this one is the 35th largest by enrollment of the 90 interventional ones that give a count, is one of 7 that started in 2006, is one of 63 in phase 2, and was the 41st registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

7 of the 98 studies testing cisplatin in Stomach Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing cisplatin in Stomach Neoplasms, or all of them as a file.
02

Study summary

Study H3E-MW- S108 is a multicenter, single arm, open-label Phase 2 study to determine the response rate of pemetrexed plus cisplatin in patients with Stage IV gastric cancer, not amenable to curative surgery, or recurrence after prior surgery, who have had no prior chemotherapy. It was planned to enroll approximately 50 patients who qualified for tumor response population.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of adenocarcinoma of the gastric. Stage IV disease, not amenable to curative surgery, or disease recurrence after prior surgery.
  • Disease status must be that of with presence of at least one measurable lesion as defined by (RECIST) criteria.
  • In bidimensionally measurable lesions the longest diameter should be selected for measurement.
  • Tumor lesions in areas of prior radiation therapy may be included only if they were clearly progressing.
  • If only a single lesion is present in a patient who had prior therapy for gastric adenocarcinoma, the neoplastic nature of the lesion should be confirmed by cytology and/or histology.
  • Ultrasound and clinical examination are not allowed for assessment of measurable disease.
  • Elevation of tumor markers, pleural or pericardial effusion, ascites, bone lesions, cystic lesions, or carcinomatous lymphangitis pulmonis/cutis is defined as not being measurable.
  • Performance Status of 0 or 1 on the (ECOG) Scale.
  • Estimated of at least 12 weeks.
  • No prior chemotherapy or radiotherapy.
  • Patient compliance and geographic proximity that allow adequate follow-up.

Adequate organ function including the following:

  • Bone marrow: 1.5 x 10 to the ninth power/liter (L), 100 x 10 to the ninth power/L, >=9 grams per deciliter (g/dL).
  • Hepatic: \<=1.5 x (ULN); alkaline phosphatase, and alanine transaminase \<=3.0 x ULN.
  • Renal: Calculated >=45 milliliters (ml)/minute.
  • Men or women, age 18 to 70 years.
  • For women: Must be surgically sterile, , or compliant with a medically approved regimen during and for 3 months after the treatment period; must have a negative serum or urine pregnancy test within 7 days before study enrollment and must not be breast-feeding.
  • For men: Must be surgically sterile, or compliant with a contraceptive regimen during and for 3 months after the treatment period.
  • Signed from patient.

Exclusion criteria

Exclusion Criteria:

  • Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
  • Concurrent administration of any other tumor therapy.
  • Active infection.
  • Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator.
  • Pregnancy.
  • Breast-feeding.
  • History of significant neurological or mental disorder, including seizures or dementia.
  • Have had a prior other than gastric cancer, carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence.
  • Patients with a history of low grade (Gleason score less than or equal to 6) localized prostate cancer will be eligible even if diagnosed less than 5 years previously.
  • Inability to interrupt aspirin or other nonsteroidal anti-inflammatory drugs 2 days before, the day of, and 2 days after the dose of pemetrexed plus cisplatin.
  • If a patient is taking a nonsteroidal anti-inflammatory drug (NSAID) or salicylate with a long half-life it should not be taken 5 days before, the day of, and 2 days after the dose of pemetrexed plus cisplatin.
  • ascites or pleural effusion that is apparent at clinical examination and cannot be controlled by drainage or other procedures prior to study enrollment. NOTE: Small effusions noted on computed tomography (CT) scan do not exclude the patient from study enrollment.
  • Inability or unwillingness to take folic acid, vitamin B12 supplementation, or dexamethasone.
  • Known or suspected . Patients who have clinical signs or symptoms that are suspicious of brain metastasis must have a pretreatment CT or magnetic resonance imaging (MRI) of the brain. A patient with documented brain metastasis, at the time of consideration for study entry or in the past, will be excluded from entering in the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Pemetrexed + Cisplatin

    Drug: pemetrexed · Drug: cisplatin

Interventions

  • 700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles

    Also known as: LY231514, Alimta

  • 75 mg/m2, IV, every 21 days x 6 cycles

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response (Objective Response Rate)

    Tumor responder is defined as participants exhibiting a best overall study response of complete response (CR; disappearance of all target lesions) or partial response (PR; 30% decrease in sum of longest diameter of target lesions). Non-responders are those who did not meet the above criteria.

    Time frame: Baseline to time of response up to six or eight 21-day cycles of treatment

Secondary outcomes

  1. Duration of Response

    Measured from the time of first documentation of CR or PR (whichever status is first recorded) until the date of time to disease progression.

    Time frame: Time of response to progressive disease up to six or eight 21-day cycles of treatment; maximum duration of study follow-up was 17.4 months

  2. Progression Free Survival (PFS)

    Defined as time from baseline to the date of disease progression or death on study, whichever occurs first. The PFS 1 definition from the United States Food and Drug Administration (FDA) draft guidance on clinical endpoints was used (FDA 2005).

    Time frame: Baseline to measured progressive disease or death up to six or eight 21-day cycles of treatment; maximum duration of study follow-up was 17.4 months

  3. Overall Survival

    Defined as the time from baseline to date of death due to any cause. Survival time is censored at the date of last contact for patients who are still alive or lost to follow up.

    Time frame: Baseline to date of death from any cause up to six or eight 21-day cycles of treatment; maximum duration of study follow-up was 17.4 months

  4. Number of Participants With Pharmacology Toxicity - Grade 3 or 4 Laboratory Toxicity Possibly Related to Study Therapy

    Common toxicity criteria (CTC) Grade 3 (severe) or 4 (life-threatening or disabling) laboratory toxicity possibly related to study therapy. A grading (severity) scale is provided for each event term. Grades range from 0 (none) to 5 (death).

    Time frame: Baseline through six or eight 21-day cycles of treatment, up to 30 days after study drug discontinuation

  5. Number of Participants With Pharmacology Toxicity - Grade 3 or 4 Non-Laboratory Toxicity Possibly Related to Study Therapy

    Common toxicity criteria (CTC) Grade 3 (severe) or 4 (life-threatening or disabling) non-laboratory toxicity possibly related to study therapy. A grading (severity) scale is provided for each event term. Grades range from 0 (none) to 5 (death).

    Time frame: Baseline through six or eight 21-day cycles of treatment, up to 30 days after study drug discontinuation

  6. Number of Participants Who Died During the Study

    Time frame: During study drug therapy up to six or eight 21-day cycles or treatment; maximum duration of study follow-up was 17.4 months

07

Results

Posted Aug 10, 2010

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + Cisplatin
Started53
Completed treatment15
Completed1
Not completed52
Withdrew: Death26
Withdrew: Lost to follow-up3
Withdrew: Physician decision13
Withdrew: Sponsor decision4
Withdrew: Withdrawal by subject6

Outcome measures

PrimaryPercentage of Participants With Objective Response (Objective Response Rate)

Tumor responder is defined as participants exhibiting a best overall study response of complete response (CR; disappearance of all target lesions) or partial response (PR; 30% decrease in sum of longest diameter of target lesions). Non-responders are those who did not meet the above criteria.

Time frame:
Baseline to time of response up to six or eight 21-day cycles of treatment
Reported as:
Number · percentage of responders
Percentage of Participants With Objective Response (Objective Response Rate)
percentage of respondersPemetrexed + Cisplatin
Responder32.1 (19.9 to 46.3)
Non-Responder67.9 (53.7 to 80.1)
SecondaryDuration of Response

Measured from the time of first documentation of CR or PR (whichever status is first recorded) until the date of time to disease progression.

Time frame:
Time of response to progressive disease up to six or eight 21-day cycles of treatment; maximum duration of study follow-up was 17.4 months
Reported as:
Median · months
Duration of Response
monthsPemetrexed + Cisplatin
Duration of Response3.8 (3.3 to 4.7)
SecondaryProgression Free Survival (PFS)

Defined as time from baseline to the date of disease progression or death on study, whichever occurs first. The PFS 1 definition from the United States Food and Drug Administration (FDA) draft guidance on clinical endpoints was used (FDA 2005).

Time frame:
Baseline to measured progressive disease or death up to six or eight 21-day cycles of treatment; maximum duration of study follow-up was 17.4 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsPemetrexed + Cisplatin
Progression Free Survival (PFS)3.7 (2.7 to 5.2)
SecondaryOverall Survival

Defined as the time from baseline to date of death due to any cause. Survival time is censored at the date of last contact for patients who are still alive or lost to follow up.

Time frame:
Baseline to date of death from any cause up to six or eight 21-day cycles of treatment; maximum duration of study follow-up was 17.4 months
Reported as:
Median · months
Overall Survival
monthsPemetrexed + Cisplatin
Overall Survival8.8 (6.0 to 9.5)
SecondaryNumber of Participants With Pharmacology Toxicity - Grade 3 or 4 Laboratory Toxicity Possibly Related to Study Therapy

Common toxicity criteria (CTC) Grade 3 (severe) or 4 (life-threatening or disabling) laboratory toxicity possibly related to study therapy. A grading (severity) scale is provided for each event term. Grades range from 0 (none) to 5 (death).

Time frame:
Baseline through six or eight 21-day cycles of treatment, up to 30 days after study drug discontinuation
Reported as:
Number · participants
Number of Participants With Pharmacology Toxicity - Grade 3 or 4 Laboratory Toxicity Possibly Related to Study Therapy
participantsPemetrexed + Cisplatin
Any Grade 3 or 4 Laboratory Toxicity29
Bone/Blood Marrow - Other1
Lymphopenia1
Platelets4
Hemoglobin6
Leukocytes (Total White Blood Cells)15
Neutrophils/Granulocytes29
Uric Acid Serum-High1
Metabolic/Laboratory - Other3
SecondaryNumber of Participants With Pharmacology Toxicity - Grade 3 or 4 Non-Laboratory Toxicity Possibly Related to Study Therapy

Common toxicity criteria (CTC) Grade 3 (severe) or 4 (life-threatening or disabling) non-laboratory toxicity possibly related to study therapy. A grading (severity) scale is provided for each event term. Grades range from 0 (none) to 5 (death).

Time frame:
Baseline through six or eight 21-day cycles of treatment, up to 30 days after study drug discontinuation
Reported as:
Number · participants
Number of Participants With Pharmacology Toxicity - Grade 3 or 4 Non-Laboratory Toxicity Possibly Related to Study Therapy
participantsPemetrexed + Cisplatin
Any Grade 3 or 4 Non-Laboratory Toxicity5
Anorexia1
Diarrhea1
Renal Failure1
Vomiting1
Nausea2
Fatigue3
SecondaryNumber of Participants Who Died During the Study
Time frame:
During study drug therapy up to six or eight 21-day cycles or treatment; maximum duration of study follow-up was 17.4 months
Reported as:
Number · participants
Number of Participants Who Died During the Study
participantsPemetrexed + Cisplatin
Study Disease18
Cardiac Failure Acute1
Death (General Disorders/Administration Site Cond)1
Intestinal Hemorrhage1
Pancytopenia1
Sudden Death3
Multi-Organ Failure1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed + Cisplatin—9/53 (17%)49/53 (92.5%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPemetrexed + Cisplatin
Sudden deathGeneral disorders3/53
PancytopeniaBlood and lymphatic system disorders2/53
Cardiac failure acuteCardiac disorders1/53
Abdominal painGastrointestinal disorders1/53
Gastrointestinal haemorrhageGastrointestinal disorders1/53
Intestinal haemorrhageGastrointestinal disorders1/53
Chest painGeneral disorders1/53
DeathGeneral disorders1/53
Multi-organ failureGeneral disorders1/53
Haemorrhagic strokeNervous system disorders1/53
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPemetrexed + Cisplatin
NeutropeniaBlood and lymphatic system disorders30/53
NauseaGastrointestinal disorders14/53
LeukopeniaBlood and lymphatic system disorders13/53
FatigueGeneral disorders13/53
White blood cell count decreasedInvestigations11/53
AnaemiaBlood and lymphatic system disorders10/53
Haemoglobin decreasedInvestigations10/53
VomitingGastrointestinal disorders9/53
Neutrophil count decreasedInvestigations8/53
Platelet count decreasedInvestigations8/53

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed + Cisplatin
Mean54.3 ± 9.85
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed + Cisplatin
Female25
Male28
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed + Cisplatin
Caucasian53
Region of Enrollment
Region of Enrollment(participants)Pemetrexed + Cisplatin
Russian Federation53
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Pemetrexed + Cisplatin
0 - Fully Active16
1 - Ambulatory, Restricted Strenuous Activity37
08

Study locations

6 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barnaul, 656049, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ivanovo, 153040, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kazan, 420029, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Moscow, 117997, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint Petersburg, 197758, Russian Federation
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stavropol, 355001, Russian Federation
09

References and documents

Publications

  • United States Food and Drug Administration (US-FDA). 2005. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (Draft Guidance). Available at: http://www.fda.gov/cder/guidance/6592dft.htm, accessed 01 November 2005. Currently available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071590.pdf, accessed 22 June 2010.
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2006
First posted
Dec 22, 2006
Start
Dec 2006
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Aug 10, 2010
Last update
Aug 17, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00415168
First posted
Dec 22, 2006
Start date
Dec 2006
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Aug 10, 2010
Last update
Aug 17, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) OR 1-317-615-4559 Mon - Fri 9 AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cisplatin

Start the discussion